Duquesne Family Office LLC
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 92%. 4 quarters of 2016 measured against SPY adj-close benchmark.
Why follow Duquesne Family Office LLC right now?
Duquesne Family Office LLC's Q1 2026 13F (period ending 2025-12-31) shows 58 positions with NTRA as the dominant holding at 13.6% of reported equity, followed by XLF at 7.1% and INSMED at 6.1%. The portfolio carries notable healthcare concentration across NTRA, INSMED, and TEVA, which together represent roughly 24% of disclosed holdings.
Notable additions include AMZN (+440% shares quarter-over-quarter) and AAL (+378%), with DAL also expanded +89%, increasing airline sector exposure. NAMS, a clinical-stage lipid-lowering company, grew +284%.
Q4 2025 reported alpha reached +9.8% against SPY (+10.8% vs +10.8% benchmark return of +10.8%); Q1 2025 showed +14.6% alpha. Past performance is not indicative of future results.
Generated from public SEC filings. Not investment advice.…
Read the full 114-word brief. Pro members get the complete editorial analysis on every curated manager, plus Sunday Pulse + Stock Picks.
Unlock with Pro — $9.99/moTop holdings · current snapshot
Source: 13F-HRRecent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Duquesne Family Office LLC
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 11:06 UTC.